MedTrace Logo

Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma

NCT01921790 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-08-22

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of avastin combined with gemcitabine, oxaliplatin, pegaspargase and dexamethasone(Avastin+ GemAOD) as first-line treatment in patients with untreated natural killer(NK)/T cell lymphoma

Conditions

  • Extranodal NK/T-cell Lymphoma, Nasal Type

Interventions

BIOLOGICAL

Avastin

Avastin 7.5mg/Kg, intravenous drip D1

DRUG

Gemcitabine

Gemcitabine 1g/m2 intravenous drip D1,D8

DRUG

Oxaliplatin

Oxaliplatin 130mg/m2 intravenous drip D1

DRUG

Pegaspargase

Pegaspargase 2500U/m2 intramuscular injection (IM) D1

DRUG

Dexamethasone

Dexamethasone 20mg/d intravenous drip D1, po D2-3

Sponsors & Collaborators

Principal Investigators

  • Wenqi Jiang, MD · Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China

  • Zhiming Li, MD · Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2015-08-31
Completion
2020-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01921790 on ClinicalTrials.gov